en.Wedoany.com Reported - Xie Yang, spokesperson for the National Health Commission and Director of the Department of Publicity, stated at a press conference held on June 1 that during the "14th Five-Year Plan" period, pediatric services in secondary and tertiary public general hospitals and maternal and child health hospitals nationwide have achieved full coverage. During the "15th Five-Year Plan" period, efforts will persist in co-prevention and co-management of multiple diseases and social co-governance, continuing to strengthen comprehensive child health services from birth to adolescence.
Data shows that by the end of 2025, 4,845 secondary and tertiary public general hospitals, 1,763 secondary and tertiary maternal and child health hospitals, and 40,000 primary healthcare institutions nationwide were able to provide pediatric services. Fu Wei, Director of the Department of Maternal and Child Health at the National Health Commission, stated that during the "15th Five-Year Plan" period, efforts will be made to strengthen systematic and continuous services for child health, including "prevention, screening, diagnosis, treatment, rehabilitation, and management." Specific measures include implementing early pregnancy care initiatives, plans to enhance the capacity for preventing birth defects and improving prenatal and postnatal care, supporting the establishment of normalized collaboration mechanisms between medical and health institutions and childcare facilities, and strengthening prevention, screening, referral, and follow-up services for child health issues.
The National Health Commission, in collaboration with 12 other departments, has also launched the "Five Health" promotion initiative for children and adolescents, targeting prominent health issues such as overweight and obesity, myopia, mental health, scoliosis, and dental caries, promoting co-prevention and co-management of multiple diseases and strengthening social co-governance.
Regarding the supply guarantee of pediatric medications, Gong Xiangguang, Director of the Department of Pharmaceutical Policy at the National Health Commission, introduced that the Commission recently issued the "Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Pediatric Medications" in conjunction with relevant departments, proposing 16 measures covering the entire chain of pediatric medication research and development, production, supply, use, payment, and supervision. Gong Xiangguang explained that eligible patents related to pediatric medications will receive patent term compensation to address the issue of enterprises being "reluctant to research and develop or unwilling to produce." Relevant departments will accelerate the research and development of innovative pediatric medications by improving lists and exploring the establishment of clinical trial collaboration networks, while also strengthening the production and supply of pediatric medications and increasing the availability of pediatric pharmaceutical services.
Gong Xiangguang stated that for a small number of specific clinically urgently needed medications that are already marketed abroad but not available domestically, since 2022, the National Health Commission, in collaboration with the National Medical Products Administration, has conducted temporary import evaluations for 51 drugs to meet the medication needs for specific diseases. This includes over 10 drugs such as defibrotide and vosoritide, which are used for pediatric rare diseases like achondroplasia and hepatic veno-occlusive disease, as well as anti-tumor medications, and have already entered clinical use.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
